US Patent Issued to INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT REGIONAL DU CANCER DE MONTPELLIER, UNIVERSITE DE MONTPELLIER, SORBONNE UNIVERSITE on Oct. 14 for "Anti-mullerian inhibiting substance antibodies and uses thereof" (French Inventors)

Posted On: 2025-10-21

ALEXANDRIA, Va., Oct. 21 -- United States Patent no. 12,441,788, issued on Oct. 14, was assigned to INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris), INSTITUT REGIONAL DU CANCER DE MONTPELLIER (Montpellier, France), UNIVERSITE DE MONTPELLIER (Montpellier, France) and SORBONNE UNIVERSITE (Paris).

"Anti-mullerian inhibiting substance antibodies and uses thereof" was invented by Andre Pelegrin (Montpellier, France), Bruno Robert (Montpellier, France), Pierre Martineau (Montpellier, France), Maeva Chauvin (Montpellier, France), Myriam Chentouf (Montpellier, France) and Nathalie Di Clemente-Besse (Paris).

According to the abstract* released by the U.S. Patent & Trademark Office: "In ovarian carcinoma, Mullerian Inhibi...

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

US Patent Issued to INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT REGIONAL DU CANCER DE MONTPELLIER, UNIVERSITE DE MONTPELLIER, SORBONNE UNIVERSITE on Oct. 14 for "Anti-mullerian inhibiting substance antibodies and uses thereof" (French Inventors)